Tanya Wilcox
Cardiovascular Disease · New York, NYNPI 1851749063
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,220 of the $8,516 with a category attached, or 96.5%. Novo Nordisk accounts for 96.5% of it on its own, with 2 other manufacturers making up the rest.
Across 9 payments — averaging $946.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$8K
- Novartis$211
- Regeneron Healthcare Solutions, Inc.$85
Across 4 payments — averaging $42,574 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$170K
- Amgen$179
What the payments were for
- Consulting fees$8,22097%
- Food & beverage$2963%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 5 | $8,220 |
| Novartis | 3 | $211 |
| Regeneron Healthcare Solutions, Inc. | 1 | $85 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,516 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $21,749 |
| Repatha SureclickEvolocumab | 32 | $17,799 |
| Metoprolol Succinate | 40 | $516 |
| Rosuvastatin Calcium | 46 | $500 |
| Ezetimibe | 18 | $465 |
| Atorvastatin Calcium | 43 | $409 |
| Bumetanide | 16 | $375 |
| Potassium Chloride | 11 | $366 |
| Spironolactone | 48 | $322 |
| Furosemide | 33 | $193 |
| Losartan Potassium | 18 | $186 |
| Lisinopril | 20 | $157 |
| ClopidogrelClopidogrel Bisulfate | 19 | $148 |
| Nitroglycerin | 14 | $90 |
| Carvedilol | 12 | $58 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.